financetom
Business
financetom
/
Business
/
Raymond James Acquires GreensLedge to Strengthen Capital Markets and Advisory Platform
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Raymond James Acquires GreensLedge to Strengthen Capital Markets and Advisory Platform
Oct 14, 2025 6:38 AM

ST. PETERSBURG, Fla.--(BUSINESS WIRE)--

Raymond James is deepening its capital markets capabilities through the acquisition of a majority stake in GreensLedge Holdings LLC, a boutique investment bank known for its leadership in structured credit and securitization. Founded in 2008, GreensLedge has built a reputation for excellence combining strategic advisory services with arranging CLOs, CDOs, Rated Feeders, CFOs, ABS and debt offerings.

The acquisition formalizes a longstanding relationship between the two firms, built on mutual respect, shared values and a commitment to client success. Raymond James will acquire a majority ownership stake, while Sumitomo Mitsui Trust Group, Inc., a trusted GreensLedge partner, will retain a minority interest. The closing of the acquisition is subject to the satisfaction of customary conditions, including regulatory approvals.

“We’re excited to take this next step with the GreensLedge team,” said Jim Bunn, president of Capital Markets and Advisory at Raymond James. “Their specialized expertise in structured products, paired with our robust fixed-income distribution and trading capabilities, unites best-in-class strengths, forming a compelling strategic partnership. More importantly, our cultural alignment and collaborative spirit will drive innovation and deliver meaningful value to our institutional clients.”

GreensLedge is led by managing partners James “Jim” Kane, Brian Zeitlin, Lesley Goldwasser and Ken Wormser – each bringing decades of capital markets experience and a shared commitment to entrepreneurial thinking and client-focused execution.

“What distinguishes GreensLedge is its nimble, capital-light model, which allows the firm to adapt quickly to changing market conditions and focus deeply on high-engagement opportunities,” said Horace Carter, president of Fixed Income at Raymond James. “Their approach and mindset are a natural fit with Raymond James’ values and culture.”

The partnership also opens the door to new synergies across Raymond James’ broader platform, including Raymond James Investment Management, Raymond James Bank, the Private Capital Advisory, Financial Services and Real Estate investment banking teams, and the Private Client Group’s ultra-high-net-worth offerings. Furthermore, Raymond James will continue to explore collaborative opportunities within capital markets to build on GreensLedge’s strong existing partnership with Sumitomo Mitsui Trust Group.

“Joining forces with Raymond James is a pivotal moment for our firm,” said Jim Kane. “Their expansive institutional distribution network, deep bench of expertise and client-first ethos align perfectly with our vision.” Brian Zeitlin continues, “After 17 years as an independent firm, we’re energized by the opportunities ahead and confident in the scale and growth we can achieve together.”

“We’re extremely proud of the business we have built over the years. Without our team’s trust and dedication, GreensLedge wouldn’t be where it is today,” shared Lesley Goldwasser. “The decision to partner with Raymond James was made with our employees and clients foremost in our minds. We believe strongly in our shared vision for delivering service without compromise,” said Ken Wormser.

Sullivan & Cromwell acted as legal advisor to Raymond James in connection with the transaction. Houlihan Lokey acted as financial advisor and Debevoise & Plimpton as legal advisor to GreensLedge in connection with the transaction.

About Raymond James Financial, Inc. ( RJF )

Raymond James Financial, Inc. ( RJF ) is a leading diversified financial services company providing private client group, capital markets, asset management, banking and other services to individuals, corporations and municipalities. Total client assets are $1.69 trillion. Public since 1983, the firm is listed on the New York Stock Exchange under the symbol RJF. Additional information is available at www.raymondjames.com.

Source: Raymond James Financial ( RJF )

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
RTX Unit Raytheon Awarded $515 Million Contract for Radar Support for US Navy, Germany
RTX Unit Raytheon Awarded $515 Million Contract for Radar Support for US Navy, Germany
Jun 3, 2026
09:27 AM EDT, 06/03/2026 (MT Newswires) -- RTX (RTX) said Wednesday that its Raytheon unit has been awarded a $515 million contract from the US Navy for the SPY-6 family of radars. The company said the sole source award contract is a follow-on to the Integration and Production Support contract, which it won in June of last year, and includes...
Eagle Plains And Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, Saskatchewan
Eagle Plains And Xcite Define Prospective Geophysical Trends at Beaver River Uranium Project, Saskatchewan
Jun 3, 2026
09:23 AM EDT, 06/03/2026 (MT Newswires) -- Eagle Plains Resources ( EGPLF ) with partner, Xcite Uranium ( XRIUF ) provided initial geophysical results for its 4502 hectares Beaver River Uranium Project, on Wednesday. Strong correlations exist between areas of known uranium mineralization at the VIC and COMBINED zones with trends of anomalous conductivity, the companies said. The Calculated Vertical...
CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise
CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise
Jun 3, 2026
09:21 AM EDT, 06/03/2026 (MT Newswires) -- CytomX Therapeutics ( CTMX ) said Wednesday it is expanding a licensing agreement with Regeneron Pharmaceuticals ( REGN ) to develop conditionally activated bispecific cancer treatments. CytomX said it will receive a $37 million target nomination payment for two newly chosen development programs. Regeneron holds the right to select up to six more...
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
Arcus Biosciences Partners With Bristol Myers Squibb to Develop Kidney Cancer Treatment
Jun 3, 2026
09:20 AM EDT, 06/03/2026 (MT Newswires) -- Arcus Biosciences ( RCUS ) said Wednesday it is partnering with Bristol Myers Squibb ( BMY ) to develop a treatment regimen for kidney cancer. Arcus said that under the agreement, it will supply its casdatifan drug, which will be evaluated in a Bristol Myers Squibb ( BMY )-sponsored phase 1/2 clinical trial....
Copyright 2023-2026 - www.financetom.com All Rights Reserved